Induction of tolerance to transplantation carbohydrate antigens is of clinical significance in recipients of ABOincompatible allografts, or of xenografts. The experimental animal model used for studying such tolerance was that of a1,3galactosyltransferase (a1,3GT) knockout (KO) mice, which lacks the a-gal epitope (Gala1-3Galb1-4GlcNAc-R) and which can produce the anti-Gal antibody against it. In contrast, wild-type (WT) mice synthesize the a-gal epitope and are immunotolerant to it. KO lymphocytes transduced in vitro with adenovirus containing the a1,3GT gene (AdaGT) express a-gal epitopes. Administration of such lymphocytes into KO mice resulted in tolerization of naïve and memory anti-Gal B cells. Mice tolerized by AdaGT transduced lymphocytes failed to produce anti-Gal following immunizations with pig kidney membranes (PKM) expressing multiple a-gal epitopes. This tolerance was perpetuated by transplanted syngeneic WT mouse hearts expressing a-gal epitopes. Transplanted WT hearts survived in the tolerized KO mice for at least 100 days, despite repeated PKM immunizations. Control mice receiving lymphocytes transduced with adenovirus lacking the a1,3GT gene were not tolerized, but produced anti-Gal and rejected transplanted WT hearts. This study suggests that autologous lymphocytes transduced with adenovirus containing A or B transferase genes may induce a similar tolerance to blood group antigens in humans.
Introduction
Studies on tolerance induction to incompatible transplantation carbohydrate antigens on mammalian cells have been feasible in the a1,3galactosyltransferase (a1,3GT) knockout mouse (KO mouse), which lacks agal epitopes (Gala1-3Galb1-4GlcNAc-R). [1] [2] [3] [4] [5] [6] [7] The a-gal epitope is a carbohydrate antigen naturally expressed on cells of nonprimate mammals and New World monkeys and is absent in humans, apes and Old World monkeys, all of which produce large amounts of the natural anti-Gal antibody that interacts specifically with this epitope. [8] [9] [10] [11] [12] Binding of the natural anti-Gal antibody to a-gal epitopes on pig xenografts induces rapid rejection of such grafts in humans or monkeys. [13] [14] [15] [16] Wild-type (WT) mice express an abundance of a-gal epitopes, similar to other nonprimate mammals. 8 This is because nonprimate mammals have an active a1,3GT gene, which encodes for the glycosyltransferase that synthesizes a-gal epitopes. 8, 17, 18 Therefore, WT mice are immunotolerant to the a-gal epitope, as it is a selfantigen in these mice, and are incapable of producing the anti-Gal antibody. 19 In contrast, KO mice lack the a-gal epitope 1, 20 and thus are not immunotolerant to it and can produce anti-Gal IgG in high titers when immunized with xenogeneic cell membranes expressing a-gal epitopes. 21, 22 In our previous studies 6, 7 we have observed that when anti-Gal B cells engage a-gal epitopes on 'syngeneic' WT mouse lymphocytes (ie lymphocytes expressing the same antigenic make-up as KO lymphocytes, with the exception that WT lymphocytes also express a-gal epitopes), these B cells are tolerized. This tolerance induction was found to be associated with the absence of T-cell help for the B cells that interact with a-gal epitopes on WT lymphocytes. 7 Based on these observations, we hypothesized that autologous KO lymphocytes manipulated to express a-gal epitopes may induce similar tolerance on anti-Gal B cells in KO mice. We further hypothesized that expression of a-gal epitopes on KO lymphocytes may be achieved by their in vitro transduction with a replicationdefective adenovirus vector that contains the a1,3GT gene. The present study demonstrates in vivo long-term tolerization of anti-Gal B cells by a gene therapy method that uses KO lymphocytes transduced in vitro with adenovirus containing the a1,3GT gene (AdaGT). Studies on the mechanism of this tolerance suggest that it is associated with the elimination of functional anti-Gal B cells after they engage the a-gal epitopes on AdaGTtransduced lymphocytes.
Results

Expression of a-gal epitopes on transduced KO lymphocytes
Expression of a-gal epitopes on cells lacking it was achieved by the use of a replication-defective adenovirus vector, containing the ORF of the mouse a1,3GT gene. 23 This adenovirus vector, designated AdaGT, was found to transduce effectively human HeLa cells and induce the expression of B2 Â 10 6 a-gal epitopes/cell, within 24 h post transduction. 23 The efficacy of AdaGT transduction in inducing a-gal epitope expression on KO lymphocytes was analyzed at various days following administration of transduced lymphocytes into irradiated KO mice.
Expression of a-gal epitopes was determined by the binding of FITC-coupled Griffonia (Bandeiraea) simplicifolia IB 4 lectin (BS lectin), which interacts specifically with a-gal epitopes 24 and thus stains WT spleen lymphocytes (Figure 1h ) but not KO spleen lymphocytes (Figure 1g ). KO spleen lymphocytes obtained from the recipient of AdaGT transduced lymphocytes demonstrated expression of this epitope on 10-20% of spleen lymphocytes on days 1-3 post transduction (Figures 1b-d) . However, this expression was only marginal on day 4 ( Figure 1e ) and was not detected on day 7 (Figure 1f ). KO lymphocytes transduced with control 'empty' adenovirus vector 25 expressed no a-gal epitopes at any of the time points (Figure 1a) .
We hypothesized that the observed diminished expression of a-gal epitopes on AdaGT transduced lymphocytes may be the result of destruction of the AdaGT genome by cellular endonucleases, within several days post transduction. To test this hypothesis, a PCR analysis for amplification of the intact exon 9 of a1,3GT gene was performed. This exon can be amplified from as little as 3 ng of WT lymphocyte DNA to yield a PCR product of 628 bp (Figure 2a) . In KO mice, exon 9 of the a1,3GT gene is disrupted by neomycin resistance gene 1 and, therefore, is not amplified by PCR. Amplification of exon 9 occurs only if it is introduced into the cells in its intact form by the transducing AdaGT vector. The intact exon 9 was readily amplified from 100 ng DNA template of KO lymphocytes transduced with AdaGT, 24 h post transduction (Figure 2b ). Amplification of exon 9 within AdaGT transduced lymphocytes gradually decreased when the DNA template was obtained from lymphocytes on days 2 and 3, and could not be detected in DNA obtained from lymphocytes on day 4 post transduction ( Figure 2c ). These mice were also studied for the presence of AdaGT in mesenteric and axillary lymph nodes and in the bone marrow. All PCR results Tolerance to carbohydrate antigen by gene therapy H Ogawa et al were found to be negative for exon 9 when measured on day 4. This implied that the lack of spleen lymphocytes expressing a-gal epitopes on day 4 was indeed the result of the destruction of intracellular AdaGT and not because such cells migrated to other lymphoid organs.
Analysis of a-gal epitope expression in various lymphoid populations indicated that B23% of AdaGT transduced T cells (stained with anti-CD3), 15% of B cells (stained with anti-CD45R/B220) and 27% of monocytes, macrophages and dendritic cells (stained by anti-CD11b/ Mac-1) expressed this epitope on day 2 post transduction (Figures 3b, e and h, respectively). All WT populations tested displayed positive shift for BS lectin staining (Figures 3c, f and i) . In contrast, KO populations transduced with the parental adenovirus vector did not express a-gal epitopes (Figures 3a, d and g ).
Tolerance induction on naïve anti-Gal B cells by AdaGT transduced KO lymphocytes
The proportion of anti-Gal B cells in KO mice is too low for reliable identification by flow cytometry. 7, 22 Therefore, tolerization of these cells could not be monitored by flow cytometry, and had to be assessed by a functional assay measuring anti-Gal production following immunization with pig kidney membranes (PKM). Naïve nonirradiated KO mice received 20 Â 10 6 AdaGT transduced KO lymphocytes via the tail vein. Since expression of a-gal epitopes on the transduced lymphocytes is transient and is limited to only few days (Figure 1) , administration of transduced lymphocytes was repeated on days 4 and 9. Anti-Gal production was measured by ELISA after four weekly PKM immunizations that started 14 days after the first administration of AdaGT transduced KO lymphocytes. Control mice underwent a similar immunization protocol but received KO lymphocytes transduced with control parental adenovirus lacking the a1,3GT gene. 25 Whereas all 10 control mice displayed an effective anti-Gal IgG response, nine out of 10 mice receiving AdaGT transduced lymphocytes displayed no anti-Gal production, or only marginal activity (o1.0 OD at serum dilution of 1:50) of this antibody (Figure 4a ). The mean anti-Gal activity in the 10 tolerized mice was 32-fold lower than that in the control mice, that is, the mean of 0.5 OD observed in tolerized mice at serum dilution of 1:50 was observed in control mice in the 32-fold higher dilution of 1:1600 (Figure 4b ). This tolerance was specific to anti-Gal B cells, as demonstrated by ELISA studies with PKM as solidphase antigen. Mice with tolerized anti-Gal B cells produced antibodies to pig peptide xenoantigens (antinon-Gal antibodies 19 ) in titers similar to those in control mice (Figure 4c ).
Tolerization of memory anti-Gal B cells
Anti-Gal B cells in humans constitute as many as 1% of circulating B lymphocytes. 26 Many of these B cells are lymphocytes primed by the cognate carbohydrate antigen on gastrointestinal bacteria. 27, 28 Memory B cells could be generated in KO mice by four PKM immunizations, in parallel to the production of anti-Gal. 22 This elicited anti-Gal can destroy cells expressing a-gal epitopes; therefore, PKM-immunized KO mice are not suitable for studying tolerance induction by AdaGT transduced lymphocytes. Whereas anti-Gal can be effectively removed in primates by affinity columns expressing a-gal epitopes, [29] [30] [31] such a treatment is technically not feasible in mice. Nevertheless, the detrimental effect of anti-Gal could be avoided in this experimental model by adoptive transfer of 20 Â 10 6 lymphocytes from PKM-immunized KO mice (ie lymphocytes including memory anti-Gal B cells) and 20 Â 10 6 naïve KO bone marrow cells into lethally irradiated KO recipients. 7 Transferred memory anti-Gal B cells are less reactive when the recipient has an intact lymphoid system, than in lethally irradiated mice. 7 This is probably because of limitations in migration and function of transferred lymphocytes in lymphoid organs that are already 'packed' with autologous lymphocytes. Therefore, in order to measure the full potential of transferred memory anti-Gal B cells, the recipients were irradiated with 10.5 Gy. This eliminates autologous lymphocytes and allows for effective homing of the transferred lymphocytes including memory anti-Gal B cells into the recipient's lymphoid organs.
Each of the 18 mice in the control group and the 28 mice in the experimental group received 20 Â 10 6 lymphocytes including memory anti-Gal B cells from the same pool of lymphocytes obtained from PKMimmunized KO mice and 20 Â 10 6 bone marrow cells from naïve KO mice (to provide for other blood cell series). Control mice also received KO lymphocytes transduced with the parental 'empty' adenovirus vector whereas experimental mice received KO lymphocytes transduced with AdaGT. All control mice effectively produced anti-Gal IgG after two PKM immunizations Figure 5a ), which on average was 32-fold lower than that in the control group ( Figure 5b ). These findings suggest that tolerance induction in this group was not fully achieved. The mice in the tolerized group and in the control group in Figures 5a and 5b were further studied for antiGal IgM response. As shown in Figure 5c , control mice displayed effective production of anti-Gal IgM whereas tolerized mice failed to exhibit significant levels of this anti-Gal isotype.
Transplantation of WT heart expressing a-gal epitopes into tolerized mice
The suggestion that memory anti-Gal B cells are tolerized by AdaGT transduced KO lymphocytes was further Tolerance to carbohydrate antigen by gene therapy H Ogawa et al supported by studies on transplantation of 'syngeneic' mouse heart expressing a-gal epitopes (ie WT heart from C57BL/6 mice). The timeline for this study is described in Table 1 . We previously reported that transplantation of WT hearts into KO mice producing anti-Gal results in hyperacute rejection because of anti-Gal binding to a-gal epitopes on the WT endothelial cells of the transplanted heart. 6,7 Accordingly, eight of the control mice in Figures 5a and b, which were heterotopically transplanted with WT mouse heart on day 28, rejected these hearts within 30 min to 18 h (Table 1) . Our previous studies indicated A similar procedure of heterotopic transplantation of syngeneic WT heart was performed on day 28 in nine of the tolerized mice presented in Figure 5a . No transplanted WT hearts were rejected in tolerized KO mice, as evaluated by daily palpation (Table 1) . Starting 4 weeks after WT heart transplantation, the mice were repeatedly immunized with PKM every 2 weeks. The transplanted WT hearts continued to function despite these repeated immunizations ( Table 1) . Two of the transplanted WT hearts that were removed on day 45 displayed normal histologic characteristics (not shown). Three of the mice died 62-64 days post WT heart transplantation of unknown reasons, but the WT hearts in these mice were not rejected prior to death. In the remaining four mice, transplanted WT hearts continued to function for 100 days despite four PKM immunizations given after these hearts were transplanted (Table 1) . Accordingly, no antiGal production was observed in these mice, 1 week after the fourth PKM immunization (Figure 6 ). In contrast, control mice, receiving memory anti-Gal B cells from the same pool of lymphocytes as the tolerized mice, but which were not transplanted with WT heart, readily produced anti-Gal following such PKM immunizations ( Figure 6 ). These findings suggest that tolerance induced by AdaGT transduced lymphocytes is perpetuated for long periods in mice transplanted with WT heart.
Analysis of deletion or anergy of memory anti-Gal B cells in tolerized mice
Previous studies have shown that tolerance to various protein antigens can be induced either by deletion or by Mean7s.e. of anti-Gal response in the three groups of KO mice presented in Figure 5a . Statistical analysis by Student's t-test indicated significant differences between the control and both of tolerized groups at all serum dilutions (Po0.00001). (c) Production of anti-Gal IgM in the group of control mice (K) or in mice that were effectively tolerized by AdaGT transduced KO lymphocytes (J), as in Figure 5a . Data are presented as mean7s.e. of 15 mice in each group. Statistical analysis by Student's t-test indicated significant differences between the two groups at all serum dilutions (Po0.00001). Figure 6 Perpetuation of tolerance by WT heart. Anti-Gal IgG response in four irradiated KO mice that received memory anti-Gal B cells, tolerized, transplanted with WT heart and immunized four times with PKM, as described in the timeline protocol in Table 1 (J). The antibody activity was measured in the serum 1 week after the fourth PKM immunization. Anti-Gal response in control mice receiving the same primed anti-Gal B cells and immunized twice with PKM (K).
Tolerance to carbohydrate antigen by gene therapy H Ogawa et al anergy of the B cells with the corresponding specificities. [33] [34] [35] Since the proportion of physiologic memory anti-Gal B cells is low, 7, 22 the fate of these cells could not be accurately determined by flow cytometry analysis, as performed in transgenic mice. [33] [34] [35] Therefore, deletion or anergy of memory anti-Gal B cells was studied by a functional assay determining their ability to produce anti-Gal after secondary adoptive transfer. The spleens in the tolerized mice (open circles in Figure 5a ) contained B0.5 Â 10 8 lymphocytes per spleen. These lymphocytes were washed and transferred into irradiated KO mice as 20 Â 10 6 cells per mouse, 1 week after the second PKM immunization (ie on day 28). In accord with the data in Figures 1 and 2c , these transferred lymphocytes lacked cells expressing a-gal epitopes and yielded no PCR product of exon 9 of the transduced a1,3GT gene even with 500 ng DNA as template (Figure 2d ). This implied that AdaGT was absent in lymphocytes that were transferred from the tolerized mice into secondary recipients.
Five secondary recipients of lymphocytes, each from a different tolerized mouse, were immunized with PKM, 14 and 21 days post adoptive transfer. These recipients displayed no significant anti-Gal IgG response when measured on day 28 post secondary adoptive transfer (Figure 7a ). In contrast, secondary recipients of lymphocytes from the control nontolerized mice of Figure 5a displayed an effective anti-Gal response after two PKM immunizations (Figure 7a ). The effective production of anti-Gal in the latter group implies that memory anti-Gal B cells in control nontolerized mice maintained their activity and were not affected by the secondary adoptive transfer.
Previous studies indicated that anergized B cells revert into an active state within 10 days after the removal of the anergizing antigen. 34 In the present study, lymphocytes transferred from tolerized mice resided in secondary KO recipients for 14 days in the absence of a-gal epitopes. Based on the studies in Goodnow et al, 34 this period of 14 days in the secondary recipient should have sufficed for the reversion of anergized memory anti-Gal B cells into competent B cells that are activated as a result of PKM immunization. Thus, the lack of significant antiGal response in the secondary recipients suggests that memory anti-Gal B cells are physically absent, that is, they could have been deleted upon encountering a-gal epitopes on AdaGT transduced lymphocytes.
The process of tolerance induction by AdaGT transduced lymphocytes was further studied for the possible association with activity of regulatory lymphocytes, since such cells were found to control the immune response in a number of experimental models. 36, 37 To study the possible presence of regulatory lymphocytes that may downregulate activity of anti-Gal B cells in tolerized mice, the secondary adoptive transfer experiments were repeated with mixed populations of lymphocytes from tolerized mice and from PKM-immunized control mice. The secondary recipients received two PKM immunizations, starting 14 days post adoptive transfer. We assumed that if regulatory T cells are present in the tolerized mice, then such cells should downregulate the activity of memory anti-Gal B cells that originated in the control mice. The recipients of lymphocyte populations from both tolerant and control mice produced anti-Gal in titers that were only slightly lower and not significantly different from those in recipients of lymphocytes from only control mice (Figure 7b ). This suggests that even if there are regulatory T cells in tolerized mice, these cells cannot account for the effective prevention of anti-Gal response in tolerized mice of Figure 5a .
Discussion
The present study demonstrates induction of tolerance on naïve and memory anti-Gal B cells by administration of KO lymphocytes manipulated to express a-gal epitopes, following in vitro transduction of such lymphocytes with AdaGT. Studies of secondary transfer of lymphocytes from tolerized KO mice to irradiated recipients suggest that the observed tolerance is the outcome of deletion of anti-Gal B cells that engage a-gal epitopes on AdaGT transduced lymphocytes. Since the Tolerance to carbohydrate antigen by gene therapy H Ogawa et al a-gal epitope by itself lacks the ability of activating T cells, 22 it is possible that the observed tolerance is the result of anti-Gal B cells engaging cell-surface a-gal epitopes in the absence of T-cell help. We previously proposed the occurrence of such a tolerizing mechanism in KO mouse recipients of 'syngeneic' WT lymphocytes. 7 The studied anti-Gal B cells are physiologic B cells, rather than transgenic lymphocytes. Therefore, it is impossible at present to determine the exact mechanism for the Bcell elimination. This tolerance could be the result of physical deletion of these B cell or may result from changes in antigenic specificity of anti-Gal B cells following receptor editing of the immunoglobulin genes in these B cells. 38, 39 In addition, the possibility that the anti-Gal B cells are anergized for periods longer than 14 days cannot be completely excluded at present, although previous studies indicated that o10 days are required for reversion of anergized B cells into an active state. 34 Only studies in 'knock in' transgenic mice producing anti-Gal, that is, mice in which a large proportion of B cells produce anti-Gal as the product of targeted transgene inserted into the immunoglobulin gene region, will enable an accurate characterization of the mechanism for tolerance induction in this experimental model.
Not all mice were fully tolerized, as some exhibited partial production of anti-Gal (B32-fold less than control mice). Our previous studies on tolerance induction by WT lymphocytes indicated that the tolerizing WT lymphocytes and anti-Gal B cells 'need time to find each other' in order for the B cells to be tolerized. 7 Anti-Gal B cells that are not tolerized by the time of PKM immunization (ie within the period of 14 days) may be rescued from tolerance by T-cell help, resulting from the activation of helper T cells by the multiple immunogenic pig xenopeptides. 7 Activity of such rescued anti-Gal B cells may explain the low anti-Gal activity in 12 of the 28 mice treated for tolerization of memory anti-Gal B cells. It is possible that repeated administration of AdaGT transduced lymphocytes for 414 days may increase the proportion of mice that are effectively tolerized to the agal epitope.
Although the expression of a-gal epitopes on AdaGT transduced lymphocytes lasts for 3-4 days, the tolerance induced by these lymphocytes can be perpetuated for prolonged periods by the subsequent transplantation of WT heart expressing this epitope. The transplanted WT hearts continued to function in the tolerized mice for 100 days, and these mice did not produce anti-Gal despite additional PKM immunizations post transplantation (Table 1 and Figure 6 ). It is probable that newly formed anti-Gal B cells that emerge in the bone marrow in these transplanted mice 'regard' the a-gal epitope on the graft as a self-antigen and thus are tolerized by it.
Previous studies in this experimental animal model demonstrated induction of tolerance to a-gal epitopes by administration of syngeneic WT bone marrow cells expressing a-gal epitopes 2, 3 or by administration of autologous bone marrow cells transfected with retrovirus containing the a1,3GT gene. 4, 5 Our previous studies 6, 7 and the present study, all indicate that this tolerance can be induced also by cells expressing a-gal epitopes, other than bone marrow cells. Since all KO mice are syngeneic, the administered AdaGT transduced KO lymphocytes may be regarded as autologous lymphocytes inducing tolerance. The present study further raises the possibility that tolerance to a-gal epitopes may be induced by a similar method in humans. Lymphocytes obtained from the blood and transduced in vitro with AdaGT may tolerize naïve and memory anti-Gal B cells following their administration back into the patient. Tolerization of antiGal B cells by autologous lymphocytes expressing a-gal epitope is likely to require the removal of the natural antiGal from the circulation, in order to prevent destruction of the tolerizing lymphocytes by the antibody. This can be achieved by affinity column expressing synthetic a-gal epitopes. [29] [30] [31] Since the transduction of lymphocytes by AdaGT will be performed in vitro, it is probable that this method of gene therapy will not be affected by factors limiting in vivo gene therapy by adenovirus vectors, such as immune response to the virus. 40 The relevance of this method for induction of tolerance to a-gal epitopes in humans will first have to be tested in monkeys in order to determine whether this phenomenon, which is observed in mice, is also applicable to primates. If tolerance induction by autologous AdaGT transduced lymphocytes is observed in monkeys, similar induction of tolerance may be considered for incompatible blood group A (GalNAca1-3[a1-2Fuc]-Galb1-4GlcNAc-R) or B antigens (Gala1-3[a1-2Fuc]-Galb1-4GlcNAc-R). The structure of these cell-surface carbohydrate antigens is very similar to that of the a-gal epitope (Gala1-3Galb1-4GlcNAc-R). Moreover, a large proportion of anti-blood group antibodies are in fact anti-Gal antibodies that bind to the a-gal epitope that serves as the core structure for these blood group antigens. 12, 41, 42 ABO incompatibility is presently one of the major limiting factors in transplantation of allografts in humans. [43] [44] [45] [46] By using autologous lymphocytes transduced with adenovirus containing A or B transferase gene, 47 one may induce tolerance similar to that observed with AdaGT transduced lymphocytes. As with tolerance induction to the a-gal epitope, such a treatment is likely to require depletion of the corresponding anti-blood group antibody, prior to the administration of the transduced lymphocytes. If successful, this method may ultimately allow for the transplantation of kidney allografts from ABO-incompatible living donors, and transplantation of ABO-incompatible heart in patients requiring urgent heart transplantation, without the risk of rejection as a result of immune response to the incompatible blood group antigen.
Materials and methods
Mice and immunization procedures
Inbred a1,3GT KO mice lacking a-gal epitopes 1 on pure H-2b background, and their 'syngeneic' WT C57BL/6 counterpart, which differ only in that they also express agal epitopes, were used in this study. Experiments were performed with both males and females, and in compliance with the relevant laws and guidelines of the IACUC committee at Rush University, which approved the study. Activation of anti-Gal B cells and production of anti-Gal was achieved in KO mice by four weekly intraperitoneal immunizations, each with 50 mg PKM, as previously described. 6, 7, 19, 22 Tolerance to carbohydrate antigen by gene therapy H Ogawa et al
Transduction of KO lymphocytes by AdaGT
The replication-defective adenovirus vector containing the a1,3GT gene (AdaGT) was propagated in 293 cells as previously described. 23 For transduction, KO lymphocytes were incubated for 4 h with AdaGT at B1 Â 10 10 infectious units/ml in RPMI medium containing 10% fetal bovine serum. Subsequently, the lymphocytes were washed and administered into mice via the tail vein, as 20 Â 10 6 lymphocytes/mouse. Control lymphocytes were transduced with the parental 'empty' adenovirus vector, 25 lacking a1,3GT insert.
Flow cytometry analysis of a-gal epitope expression on transduced lymphocytes KO lymphocytes were incubated at a concentration of 10 Â 10 6 cells/ml for 30 min at 41C with 10 mg/ml fluoresceinated (FITC)-B. simplicifolia IB 4 lectin (BS lectin) (Sigma, St Louis, MO, USA), in PBS containing 1% BSA. This lectin binds specifically to a-gal epitopes. 24 The cells were also stained with phycoerythrin (PE) labeled antimouse CD45R/B220 and anti-CD3 (Pharmingen, San Diego, CA, USA) for identification of B and T cells, respectively. PE-conjugated anti-mouse CD11b/MAC-1 (Pharmingen) was used to stain monocytes, macrophages and dendritic cells. Cells were then washed, fixed and analyzed by FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA, USA).
PCR analysis of transduced lymphocytes
Genomic DNA was extracted from spleen lymphocytes and subjected to PCR analysis for exon 9 of mouse a1,3GT gene (ie the exon containing the catalytic domain and which is disrupted in KO mice 1 ), using primers 5 0 -AGACTTTCTGGAGTCTGCTGACAT-3 0 and 5 0 -TACCTTGACACTTTTAATATCTGA-3 0 . 17 The PCR was performed with 35 cycles, each including 30 s at 941C, 20 s at 621C and 20 s at 721C, followed by 5 min at 721C. The first cycle included 5 min at 941C to achieve complete denaturation of the DNA. The PCR yields a product of size 628 bp. Since this exon is disrupted in KO mice, a PCR product in this assay indicates the presence of the intact a1,3GT gene introduced by AdaGT, as previously demonstrated. 23 Tolerance induction by AdaGT transduced lymphocytes Tolerization of naïve anti-Gal B cells. Naïve KO mice received via the tail vein 20 Â 10 6 AdaGT transduced KO spleen lymphocytes on days 0, 4 and 9. The mice received four weekly PKM immunizations starting on day 14. Anti-Gal was determined a week after the fourth PKM immunization.
Tolerization of memory anti-Gal B cells. Spleen lymphocytes including memory anti-Gal B cells were obtained from KO mice immunized four times with PKM. 7, 22, 32 Lymphocytes pooled from PKM-immunized mice were administered as 20 Â 10 6 cells/mouse into the tail vein of lethally irradiated KO mice (10.5 Gy). These mice also received 20 Â 10 6 bone marrow cells from naïve KO mice for producing all needed blood series, and 20 Â 10 6 AdaGT transduced lymphocytes, or control 20 Â 10 6 KO lymphocytes transduced with the parental replication-defective adenovirus lacking the a1,3GT
gene. 25 Administration of transduced lymphocytes was repeated on days 4 and 9. PKM immunization was performed on days 14 and 21 post adoptive transfer and anti-Gal production determined on day 28.
ELISA studies
Production of anti-Gal IgG in KO mice immunized with PKM was measured in serially diluted serum samples by ELISA in wells coated with 10 mg/ml synthetic a-gal epitopes coupled to BSA (a-gal-BSA, Dextra, Reading, UK). 6, 7, 22, 32 After 2 h incubation, the plates were washed and incubated with peroxidase-coupled goat anti-mouse IgG (Accurate Chemicals Labs, Westbury, NY, USA) and color developed with o-phenylenediamine (Sigma). Nonspecific binding was measured in ELISA wells coated with BSA and the data were subtracted from those in corresponding serum dilutions in ELISA with agal BSA. Anti-Gal IgM was measured by the same method using goat anti-mouse IgM (Accurate Chemicals Labs) as a secondary antibody. Since PKM-immunized mice produce many IgM antibodies that bind nonspecifically to ELISA wells, 19 the sera were adsorbed on an equal volume of a-galactosidase-treated PKM (ie PKM lacking a-gal epitopes). This adsorption is performed for removal of such nonspecific IgM molecules prior to the ELISA for anti-Gal IgM.
An additional ELISA was performed for measuring production of IgG antibodies to the large variety of immunogenic pig xeno-proteins (anti-non-Gal antibodies). 19 For this purpose, PKM (1 mg/ml) were dried in ELISA wells, resulting in their firm adherence. These membranes served as solid-phase antigen. Wells were blocked with 1% BSA in PBS. The assay was performed as that measuring anti-Gal above. The sera used were depleted of anti-Gal prior to the assay, by adsorption on glutaraldehyde-fixed rabbit red cells, which express an abundance of a-gal epitopes. 8, 11, 21 Heart transplantation Heterotopic transplantation of WT mouse hearts was performed as previously described. 6, 7, 32 WT hearts from C57BL/6 donors are 'syngeneic' to KO mice but also express a-gal epitopes. KO mice were transplanted with these hearts in the abdominal cavity by connecting the WT pulmonary artery to vena cava inferior and the WT aorta to the KO aorta. At 4 weeks after transplantation, the mice were immunized with PKM every 2 weeks and tested for anti-Gal IgG response. The function of the heart was assessed by daily palpation.
